Halstenson C - Search Results

1

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.

Dimmitt DC, Shah AK, Arumugham T, Cramer MB, Halstenson C, Horton M, Weir SJ. Dimmitt DC, et al. Among authors: halstenson c. J Clin Pharmacol. 1998 Sep;38(9):798-806. J Clin Pharmacol. 1998. PMID: 9753207 Clinical Trial.

2

Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment.

Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H. Halstenson CE, et al. J Clin Pharmacol. 1992 Feb;32(2):124-32. doi: 10.1002/j.1552-4604.1992.tb03816.x. J Clin Pharmacol. 1992. PMID: 1613121

3

Pharmacokinetics of zileuton and its metabolites in patients with renal impairment.

Awni WM, Wong S, Chu SY, Patterson K, Hansen R, Machinist JM, Drajesk J, Keane WF, Halstenson CE. Awni WM, et al. Among authors: halstenson ce. J Clin Pharmacol. 1997 May;37(5):395-404. doi: 10.1002/j.1552-4604.1997.tb04317.x. J Clin Pharmacol. 1997. PMID: 9156372 Clinical Trial.

4

Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease.

Awni WM, Halstenson CE, Nayak RK, Opsahl JA, Desiraju RK, Minn FL, Matzke GR. Awni WM, et al. Among authors: halstenson ce. J Clin Pharmacol. 1995 Apr;35(4):379-83. doi: 10.1002/j.1552-4604.1995.tb04077.x. J Clin Pharmacol. 1995. PMID: 7650227

5

The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function.

Halstenson CE, Opsahl JA, Rachael K, Olson SC, Horvath AM, Abraham PA, Posvar EL. Halstenson CE, et al. J Clin Pharmacol. 1992 Apr;32(4):344-50. doi: 10.1002/j.1552-4604.1992.tb03846.x. J Clin Pharmacol. 1992. PMID: 1569237

6

Disposition of minoxidil in patients with various degrees of renal function.

Halstenson CE, Opsahl JA, Wright CE, Fleishaker JC, Andreadis NA, Sobieraj J, Matzke GR. Halstenson CE, et al. J Clin Pharmacol. 1989 Sep;29(9):798-802. doi: 10.1002/j.1552-4604.1989.tb03422.x. J Clin Pharmacol. 1989. PMID: 2808745

7

The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.

St Peter JV, Brady ME, Foote EF, Dandekar KA, Smaldone L, Pykkonen JL, Keane WF, Halstenson CE. St Peter JV, et al. Among authors: halstenson ce. Eur J Clin Pharmacol. 1993;45(1):59-63. doi: 10.1007/BF00315351. Eur J Clin Pharmacol. 1993. PMID: 8405031

8

Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers.

Guay DR, Awni WM, Halstenson CE, Findlay JW, Opsahl JA, Abraham PA, Jones EC, Matzke GR. Guay DR, et al. Among authors: halstenson ce. J Clin Pharmacol. 1987 Dec;27(12):983-7. doi: 10.1002/j.1552-4604.1987.tb05601.x. J Clin Pharmacol. 1987. PMID: 3437070

9

Pharmacokinetics of loratadine in patients with renal insufficiency.

Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, Zampaglione N. Matzke GR, et al. Among authors: halstenson ce. J Clin Pharmacol. 1990 Apr;30(4):364-71. doi: 10.1002/j.1552-4604.1990.tb03607.x. J Clin Pharmacol. 1990. PMID: 2140371

10

Disposition of famotidine in renal insufficiency.

Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR. Halstenson CE, et al. J Clin Pharmacol. 1987 Oct;27(10):782-7. doi: 10.1002/j.1552-4604.1987.tb02996.x. J Clin Pharmacol. 1987. PMID: 3429684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters